Browse

Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: A multi-center study

DC Field Value Language
dc.contributor.authorKim, Hee Seung-
dc.contributor.authorPark, Chan-Yong-
dc.contributor.authorLee, Jong-Min-
dc.contributor.authorLee, Jae-Kwan-
dc.contributor.authorKim, Seok-Mo-
dc.contributor.authorKim, Jae Weon-
dc.contributor.authorCho, Chi-Heum-
dc.date.accessioned2012-06-04T06:37:45Z-
dc.date.available2012-06-04T06:37:45Z-
dc.date.issued2010-09-
dc.identifier.citationGYNECOLOGIC ONCOLOGY; Vol.118 3; 283-288ko_KR
dc.identifier.issn0090-8258-
dc.identifier.urihttps://hdl.handle.net/10371/76795-
dc.description.abstractObjective. To evaluate the role of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer (EEC). Methods. We reviewed 413 patients with EEC from 6 tertiary medical centers between July 1996 and June 2008. All patients were divided into (1) 4 categories of preoperative serum CA-125 levels: <18 U/mL (n=203); 18-35 U/mL (n = 114); 36-70 U/mL (n = 53); >70 U/mL (n = 43) or (2) 3 categories: low-risk (n = 240); intermediate-risk (n = 99); high-risk diseases (n = 74). Results. Receiver operative curves showed the best cut-off values of 16.2-40.8 U/mL for predicting prognostic factors with 53.4-84.2% of sensitivity, 43.9-81.7% of specificity, 48.8-82.1% of positive predictive value (PPV), 48.5-83.8% of negative predictive value (NPV) and 48.6-83.0% of accuracy. Especially, adnexal involvement was predicted with the highest accuracy (83.0%) at >= 40.8 U/mL. The best cut-off values for preoperative selection of intermediate- to high-risk, and high-risk diseases were 17.3 U/mL and 21.9 U/mL (62.4% and 68.9% of sensitivity; 54.6% and 64.3% of specificity; 57.9% and 64.2% of PPV; 59.2% and 67.4% of NPV, 58.5% and 65.8% of accuracy). Furthermore, >70 U/mL of preoperative serum CA-125 levels was a prognostic factor for poor progression-free and overall survivals. Conclusions. Serum CA-125 levels may not be useful for predicting most of prognostic factors, and may not contribute to preoperative selection of patients with intermediate- or high-risk disease who need adjuvant radiotherapy in EEC. However, serum CA-125 levels may be helpful in preoperative counseling for young patients who want ovarian preservation, and >70 U/mL could be considered as a risk factor for poor survival. (C) 2010 Elsevier Inc. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherACADEMIC PRESS INC ELSEVIER SCIENCEko_KR
dc.subjectPreoperativeko_KR
dc.subjectEndometrioid endometrial cancerko_KR
dc.subjectSerum CA-125 levelsko_KR
dc.subjectPrognostic factorsko_KR
dc.subjectSurvivalko_KR
dc.titleEvaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: A multi-center studyko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김희승-
dc.contributor.AlternativeAuthor박찬용-
dc.contributor.AlternativeAuthor이종민-
dc.contributor.AlternativeAuthor이재관-
dc.contributor.AlternativeAuthor조치흠-
dc.contributor.AlternativeAuthor김석모-
dc.contributor.AlternativeAuthor김재원-
dc.identifier.doi10.1016/j.ygyno.2010.04.018-
dc.citation.journaltitleGYNECOLOGIC ONCOLOGY-
dc.description.citedreferenceKim K, 2009, J GYNECOL ONCOL, V20, P203, DOI 10.3802/jgo.2009.20.4.203-
dc.description.citedreferenceSHUSTER LT, 2008, MENOPAUSE INT, V14, P111-
dc.description.citedreferenceKim HS, 2008, ONKOLOGIE, V31, P315, DOI 10.1159/000131270-
dc.description.citedreferenceKong A, 2007, ANN ONCOL, V18, P1595, DOI 10.1093/annonc/mdm066-
dc.description.citedreferenceDENSCHLAG D, 2007, AM J OBSTET GYNECOL, V196, pE1-
dc.description.citedreferenceHeintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161-
dc.description.citedreferenceCreasman WT, 2006, INT J GYNECOL OBSTET, V95, pS105-
dc.description.citedreferenceRiedinger JM, 2006, ANN ONCOL, V17, P1234, DOI 10.1093/annonc/mdl120-
dc.description.citedreferenceTakac I, 2006, WIEN KLIN WOCHENSCHR, V118, P62, DOI 10.1007/s00508-006-0554-9-
dc.description.citedreferenceChung HH, 2006, ACTA OBSTET GYN SCAN, V85, P1501, DOI 10.1080/00016340601022777-
dc.description.citedreferenceSantillan A, 2005, J CLIN ONCOL, V23, P9338, DOI 10.1200/JCO.2005.02.2582-
dc.description.citedreferenceWalsh C, 2005, OBSTET GYNECOL, V106, P693-
dc.description.citedreferencePowell JL, 2005, J REPROD MED, V50, P585-
dc.description.citedreferenceGadducci A, 2004, BIOMED PHARMACOTHER, V58, P24, DOI 10.1016/j.biopha.2003.11.003-
dc.description.citedreferenceSantala M, 2003, ANTICANCER RES, V23, P3097-
dc.description.citedreferenceHsieh CH, 2002, GYNECOL ONCOL, V86, P28, DOI 10.1006/gyno.2002.6664-
dc.description.citedreferenceGinath S, 2002, INT J GYNECOL CANCER, V12, P372-
dc.description.citedreferenceDotters DJ, 2000, AM J OBSTET GYNECOL, V182, P1328, DOI 10.1067/mob.2000.106251-
dc.description.citedreferenceKoper NP, 1998, ANTICANCER RES, V18, P1897-
dc.description.citedreferenceSood AK, 1997, OBSTET GYNECOL, V90, P441-
dc.description.citedreferenceLo SST, 1997, TUMOR BIOL, V18, P241-
dc.description.citedreferenceSCAMBIA G, 1994, GYNECOL ONCOL, V54, P292-
dc.description.citedreferenceROSE PG, 1994, OBSTET GYNECOL, V84, P12-
dc.description.citedreferenceLEHTOVIRTA P, 1994, BRIT J OBSTET GYNAEC, V101, P532-
dc.description.citedreferenceFAYERS PM, 1993, INT J GYNECOL CANCER, V3, P285-
dc.description.citedreferenceBLOSS JD, 1991, GYNECOL ONCOL, V40, P74-
dc.description.citedreferenceSOPER JT, 1990, AM J OBSTET GYNECOL, V163, P1204-
dc.description.citedreferenceDUK JM, 1989, OBSTET GYNECOL, V73, P661-
dc.description.citedreferenceDUK JM, 1986, AM J OBSTET GYNECOL, V155, P1097-
dc.description.citedreferenceBAST RC, 1983, NEW ENGL J MED, V309, P883-
dc.description.tc1-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Obstetrics & Gynecology (산부인과전공)Journal Papers (저널논문_산부인과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse